Misplaced Pages

Rozrolimupab

Article snapshot taken from Wikipedia with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.

This is an old revision of this page, as edited by 85.24.240.67 (talk) at 09:11, 10 January 2011 (removed vandalism). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Revision as of 09:11, 10 January 2011 by 85.24.240.67 (talk) (removed vandalism)(diff) ← Previous revision | Latest revision (diff) | Newer revision → (diff)
This article is an orphan, as no other articles link to it. Please introduce links to this page from related articles; try the Find link tool for suggestions. (December 2009)
Pharmaceutical compound
Rozrolimupab
Clinical data
ATC code
  • none
Identifiers
IUPAC name
  • 1. Anti-RhD recombinant human polyclonal antibody composed of 25 unique IgG1 antibodies
    2. Recombinant human antigen-specific polyclonal antibody (pAb) against RhD antigen expressed in Chinese hamster ovary cells
CAS Number
Chemical and physical data
Molar massAntibodies in the 144.8 -148.8 kDa range

Rozrolimupab (Sym001) is a polyclonal antibody used in the treatment of autoimmune thrombocytopenic purpura, prevention of isoimmunization in Rh-negative pregnant women.

This drug was developed by Symphogen A/S.

References

  1. STATEMENT ON A NONPROPRIETARY NAME ADOPTED BY THE USAN COUNCIL - ROZROLIMUPAB, American Medical Association.


Stub icon

This pharmacology-related article is a stub. You can help Misplaced Pages by expanding it.

Categories: